Tag Archives: Imugene

JPM 2024 Analysis Days 2 & 3: Imugene, CRISPR Tx, and Precigen

On the second and third days of JPM 2024, Celltelligence covered presentations by Imugene (webcast / presentation), CRISPR Tx (press release / webcast), and Precigen (webcast / presentation). Below, Celltelligence provides insights and context for each presentation. The following topics are covered: 

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Precision and Imugene Agree on Terms for the Transfer of Azer-cel; Precision to Deprioritize its Cell Therapy Franchise

On Tuesday, August 15, Precision Biosciences announced (press release) a strategic transaction with Imugene for the exclusive WW licensing of azer-cel (PBCAR0191; allogeneic CD19 CAR-T) in oncology, which also included option to develop up to 3 other cancer programs. Additionally, Imugene disclosed (press release) its intention to continue azer-cel’s Ph1/2a trial in ≥3L NHL and r/r ALL, while planning the initiation of a potentially registrational trial in 2024. Below, Celltelligence provides insights on azer-cel’s transaction agreement, while analyzing the possible therapeutic potential of the combination of the licensed CD19 CAR-T with Imugene’s proprietary onCARlytics platform.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.